During the double-blind withdrawal period, 41.9% of ecopipam-treated patients relapsed compared with 68.1% of placebo-treated patients. Topline data were announced from a phase 3 trial evaluating ...
Whereas the postsynaptic antagonist actions of OPC-4392 are ... conducted at each of the known molecular isoforms of the dopamine receptors in several transfection systems, as well as at novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback